Lactic Acidosis Cell Models for Research

Lactic acidosis is a metabolic disturbance characterized by elevated blood lactate levels (typically >5 mmol/L) and decreased blood pH (<7.35). It is a common complication in critically ill patients, with an incidence of 1-2% in hospitalized patients and up to 16% in intensive care units. Mortality rates are high, ranging from 30% to 60% depending on the underlying cause. Type A lactic acidosis results from tissue hypoperfusion or hypoxia, while Type B arises from metabolic disorders, drugs, or toxins. Key risk factors include sepsis, cardiac failure, liver disease, and certain medications (e.g., metformin, linezolid). The condition is a significant clinical challenge, and understanding its molecular basis is crucial for developing targeted therapies.

Lactic acidosis is an ideal model for studying cellular metabolism, pH regulation, and mitochondrial function. Its subtypes (Type A and B) offer distinct mechanistic insights. Public datasets, such as those from the Gene Expression Omnibus (GEO), provide transcriptomic and metabolomic data from patient samples and experimental models. Open questions include the precise role of lactate transporters in tumor acidosis, the interplay between glycolysis and oxidative phosphorylation, and the identification of therapeutic targets to modulate lactate production or clearance.

• • Lactic acidosis is not a cancer itself but is often associated with tumors due to the Warburg effect. Key pathways include:
• • Glycolysis: Enhanced glucose uptake and conversion to lactate via LDHA.
• • Mitochondrial dysfunction: Impaired oxidative phosphorylation leading to increased lactate production.
• • pH regulation: Upregulation of monocarboxylate transporters (MCT1, MCT4) and carbonic anhydrases to export lactate and protons.
• • Hypoxia-inducible factor (HIF) signaling: HIF-1α upregulates glycolytic enzymes and transporters under hypoxic conditions.

Data from TCGA and COSMIC.

• • Key signaling networks involved in lactic acidosis include:
• • PI3K/AKT/mTOR pathway: Promotes glycolysis and lactate production.
• • HIF-1α signaling: Activates transcription of glycolytic enzymes and transporters.
• • p53 pathway: Loss of p53 enhances glycolysis.
• • MYC signaling: Upregulates LDHA and other glycolytic genes.
• • AMPK pathway: Responds to energy stress and modulates metabolism.

Organoids derived from patient tissues can recapitulate the 3D architecture and metabolic microenvironment, providing more physiologically relevant models.

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice, preserving patient-specific mutations.
• • Genetically engineered mouse models (GEMM): Knock-in or knockout of genes like Ldha or Mct4 to study lactic acidosis in vivo.
• • Chemically induced models: Administration of drugs like metformin or phenformin to induce lactic acidosis in rodents.

• • CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications. For lactic acidosis research, common models include:
• • LDHA knockout cell lines: Abolish lactate production, allowing study of glycolysis dependence.
• • LDHB knockout cell lines: Impair lactate oxidation, increasing lactate accumulation.
• • MCT4 knockout cell lines: Block lactate export, causing intracellular acidosis.
• • PDK1 knock-in cell lines: Overexpress PDK1 to mimic glycolytic shift.

These sequence-verified models are commercially available and accelerate research by providing reproducible, isogenic backgrounds. They are essential for functional validation and drug screening.

Knockout and knock-in cell lines are used to validate the role of specific genes in lactic acidosis. For example, LDHA knockout cells show reduced lactate production and increased sensitivity to glycolytic inhibitors. Knock-in of mutant IDH1 (not directly related but example) can be used to study oncometabolites. These models help dissect the contribution of individual genes to the metabolic phenotype.

Isogenic pairs (e.g., wild-type vs. LDHA knockout) are used in high-throughput screens to identify compounds that selectively kill cells with a particular metabolic dependency. Resistance mechanisms can be studied by exposing cells to increasing concentrations of drugs and selecting for resistant clones, then analyzing genetic changes.

CRISPR-based synthetic lethality screens can identify genes whose knockout is lethal only in the context of lactic acidosis. This can reveal novel therapeutic targets and biomarkers. For example, screening in LDHA-deficient cells may identify compensatory pathways that can be targeted.